Human appetite control by glucagon-like peptide receptor binding compounds
AssigneeAmylin Pharmaceuticals, Inc.
InventorsBurkhard Goke, Christoph Beglinger, Thomas R. Coolidge
Life of this patent
Estimating the term…
Abstract
A composition including a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier. The amount of the compound present is effective to control appetite in a human. Also disclosed is a method for controlling appetite and for reducing food intake in a human by administering to the human a composition comprising a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier.
Claims19
A method for controlling appetite in a human comprising:
- peripherally administering to a human a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier, wherein said compound comprises GLP-1 (1–37), GLP-1 (7–37), GLP-1 (7–36) or a biologically active analog of GLP-1 (1–37), GLP-1 (7–37), GLP-1 (7–36) in an amount effective to control appetite in a human, wherein said biologically active analog of GLP-1 (1–37), GLP-1 (7–37), GLP-1 (7–36) contains one or more substitutions, deletions or insertions of not more than five amino acids from the amino acid sequence of GLP-1 (1–37), GLP-1 (7–37), or GLP-1 (7–36).
A method for reducing food intake in a human comprising:
- peripherally administering to a human a compound which binds to the receptor for glucagon-like peptide-1 and a pharmaceutical carrier, wherein said compound comprises GLP-1 (1–37), GLP-1 (7–37), GLP-1 (7–36) or a biologically active analog of GLP-1 (1–37), GLP-1 (7–37), a human, wherein said biologically active analog of GLP-1 (1–37), GLP-1 (7–37), GLP-1(7–36) contains one or more substitutions, deletions or insertions of not more than five amino acids from the amino acid sequence of GLP-1 (1–37), GLP-1 (7–37), or GLP-1 (7–36).
A method for controlling appetite in a human with diabetes comprising:
- peripherally administering to a human having diabetes a compound which binds to the receptor for glucagon-like peptide-1 and a pharmaceutical carrier, wherein said compound comprises GLP-1 (1–37), GLP-1 (7–37), GLP-1 (7–36) or a biologically active analog of GLP-1 (1–37), GLP-1 (7–37), GLP-1 (7–36) in an amount effective to control appetite in a human with diabetes, wherein said biologically active analog of GLP-1 (1–37), GLP-1 (7–37), GLP-1 (7–36) contains one or more substitutions, deletions or insertions of not more than five amino acids from the amino acid sequence of GLP-1 (1–37), GLP-1 (7–37), or GLP-1 (7–36).
A composition for suppressing appetite in a human comprising:
- a compound prepared for intravenous administration in a dose range of from about 0.1 pmol to about 5.0 pmol/kg min which binds to a receptor for glucagon-like peptide-1, and a pharmaceutical carrier, wherein said compound comprises GLP-1(1–37), GLP-1 (7–37), GLP-1 (7–36) or a biologically active analog of GLP-1 (1–37), GLP-1 (7–37), GLP-1 (7–36) wherein said biologically active analog of GLP-1 (1–37), GLP-1 (7–37), GLP-1 (7–36) contains one or more substitutions deletions or insertions of not more than five amino acids from the amino acid sequence of GLP-1 (1–37), GLP-1 (7–37), or GLP-1 (7–36).
Dependencies are inferred from the claim text.